Bionano Genomics Inc - Asset Resilience Ratio

Latest as of December 2025: 13.95%

Bionano Genomics Inc (BNGO) has an Asset Resilience Ratio of 13.95% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check strategic asset allocation of Bionano Genomics Inc to assess the company's strategic physical and investment asset allocation.

Liquid Assets

$10.27 Million
Cash + Short-term Investments

Total Assets

$73.58 Million
All company assets

Resilience Assessment

Moderate
Financial Resilience Level

Asset Resilience Ratio Trend (2020–2025)

This chart shows how Bionano Genomics Inc's Asset Resilience Ratio has changed over time. See Bionano Genomics Inc (BNGO) balance sheet quality index to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Bionano Genomics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Bionano Genomics Inc market cap and net worth.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents $0.00 0%
Short-term Investments $10.27 Million 13.95%
Total Liquid Assets $10.27 Million 13.95%

Asset Resilience Insights

  • Moderate Liquidity: Bionano Genomics Inc has 13.95% of assets in liquid form.
  • While adequate for normal operations, this level may limit flexibility during economic stress.
  • The company has significant short-term investments, indicating active treasury management.

Bionano Genomics Inc Industry Peers by Asset Resilience Ratio

Compare Bionano Genomics Inc's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Andon Health Co Ltd
SHE:002432
Medical Instruments & Supplies 18.11%
AVE Science & Technology Co Ltd
SHG:688067
Medical Instruments & Supplies 24.13%
Ansell Ltd
AU:ANN
Medical Instruments & Supplies 7.53%
Nanosonics Ltd
AU:NAN
Medical Instruments & Supplies 46.84%
SDI Ltd
AU:SDI
Medical Instruments & Supplies 3.36%
Austco Healthcare Ltd
AU:AHC
Medical Instruments & Supplies 15.90%
Trajan Group Holdings Ltd
AU:TRJ
Medical Instruments & Supplies 0.29%
Osteopore Ltd
AU:OSX
Medical Instruments & Supplies 22.60%

Annual Asset Resilience Ratio for Bionano Genomics Inc (2020–2025)

The table below shows the annual Asset Resilience Ratio data for Bionano Genomics Inc.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 13.95% $10.27 Million $73.58 Million +13.56pp
2024-12-31 0.39% $302.00K $76.67 Million -22.38pp
2023-12-31 22.77% $48.82 Million $214.40 Million -12.38pp
2022-12-31 35.15% $108.09 Million $307.50 Million -24.79pp
2021-12-31 59.94% $226.04 Million $377.10 Million --
2020-12-31 0.00% $0.00 $60.45 Million --
pp = percentage points

About Bionano Genomics Inc

NASDAQ:BNGO USA Medical Instruments & Supplies
Market Cap
$12.87 Million
Market Cap Rank
#26418 Global
#5452 in USA
Share Price
$1.16
Change (1 day)
+0.87%
52-Week Range
$1.09 - $4.92
All Time High
$155.70
About

Bionano Genomics, Inc., together with its subsidiaries, provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, China, Japan, South Korea, Singapore, India, and Australia. The company offers genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simpl… Read more